002750.SZ
Kunming Longjin Pharmaceutical Co., Ltd. [002750.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002750.SZ Stock Summary
Top 002750.SZ Correlated Resources
002750.SZ
Top 10 Correlated ETFs
002750.SZ
Top 10 Correlated Stocks
002750.SZ
002750.SZ Financial details
Company Rating
Buy
Market Cap
5.31B
Income
-1.62M
Revenue
299.05M
Book val./share
1.6
Cash/share
1.05
Dividend
-
Dividend %
-
Employees
517
Optionable
No
Shortable
Yes
Earnings
29 Apr 2022
P/E
-3249.12
Forward P/E
-
PEG
285.14
P/S
17.57
P/B
8.27
P/C
12.63
P/FCF
-173.85
Quick Ratio
4.17
Current Ratio
5.05
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
-0
EPS next Y
-
EPS next Q
-
EPS this Y
-73.9%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-38.54%
Revenue last 5Y
18.2%
Revenue Q/Q
-19.24%
EPS Q/Q
-74.22%
-
-
-
-
SMA20
16.67%
SMA50
40%
SMA100
16.67%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-0.01%
Gross Margin
47%
Oper. Margin
-2%
Profit Margin
-1%
Payout
-
Shs Outstand
400.5M
Shs Float
156.89M
-
-
-
-
Target Price
-
52W Range
7.16-24.33
52W High
-44.75%
52W Low
+89.43%
RSI
48
Rel Volume
0.55
Avg Volume
33.57M
Volume
18.6M
Perf Week
0.38%
Perf Month
19.14%
Perf Quarter
11.34%
Perf Half Y
17.87%
-
-
-
-
Beta
0.488454
-
-
Volatility
0.27%, 1.82%
Prev Close
0.84%
Price
13.26
Change
-4.05%
002750.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.76 | 0.84 | 0.69 | 0.63 | 1.75 | |
| Net income per share | 0.09 | 0.03 | -0.06 | 0.03 | 0.01 | |
| Operating cash flow per share | 0.14 | 0.08 | 0.01 | -0.02 | -0.04 | |
| Free cash flow per share | 0.1 | 0.04 | -0.01 | -0.08 | -0.06 | |
| Cash per share | 0.18 | 0.96 | 1.01 | 1.03 | 1.07 | |
| Book value per share | 1.61 | 1.61 | 1.56 | 1.59 | 1.59 | |
| Tangible book value per share | 1.57 | 1.56 | 1.53 | 1.64 | 1.57 | |
| Share holders equity per share | 1.61 | 1.61 | 1.56 | 1.59 | 1.59 | |
| Interest debt per share | 0 | 0.03 | 0 | 0 | 0 | |
| Market cap | 3.64B | 2.26B | 4.97B | 3.28B | 5.2B | |
| Enterprise value | 3.57B | 1.87B | 4.77B | 3.16B | 5.1B | |
| P/E ratio | 103.53 | 162.72 | -214.9 | 277.63 | 1.68K | |
| Price to sales ratio | 11.96 | 6.72 | 18.04 | 12.91 | 7.41 | |
| POCF ratio | 62.7 | 71.2 | 1.23K | -483.88 | -351.42 | |
| PFCF ratio | 89.84 | 139.6 | -1.64K | -107.92 | -206.82 | |
| P/B Ratio | 5.64 | 3.49 | 7.96 | 5.16 | 8.14 | |
| PTB ratio | 5.64 | 3.49 | 7.96 | 5.16 | 8.14 | |
| EV to sales | 11.72 | 5.57 | 17.33 | 12.42 | 7.26 | |
| Enterprise value over EBITDA | 55.96 | 38.37 | 1.03K | 79.61 | 140.57 | |
| EV to operating cash flow | 61.48 | 59.08 | 1.18K | -465.59 | -344.62 | |
| EV to free cash flow | 88.09 | 115.83 | -1.57K | -103.84 | -202.81 | |
| Earnings yield | 0.01 | 0.01 | 0 | 0 | 0 | |
| Free cash flow yield | 0.01 | 0.01 | 0 | -0.01 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0.18 | 0.17 | 0.17 | 0.16 | 0.18 | |
| Net debt to EBITDA | -1.11 | -7.87 | -42.15 | -3.13 | -2.78 | |
| Current ratio | 4.28 | 4.75 | 4.56 | 5.18 | 4.61 | |
| Interest coverage | 39.14 | 0.39 | 0 | 0 | -11.64 | |
| Income quality | 1.65 | 2.29 | -0.17 | -0.57 | -4.79 | |
| Dividend Yield | 0.02 | 0.01 | 0 | 0 | 0 | |
| Payout ratio | 1.71 | 0.87 | 0 | 0 | 0.13 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.01 | |
| Research and developement to revenue | 0.09 | 0.1 | 0.08 | 0.08 | 0.03 | |
| Intangibles to total assets | 0.02 | 0.04 | 0.06 | 0.06 | 0.06 | |
| Capex to operating cash flow | -0.3 | -0.49 | -1.75 | 3.48 | 0.7 | |
| Capex to revenue | -0.06 | -0.05 | -0.03 | -0.09 | -0.01 | |
| Capex to depreciation | -0.79 | -0.68 | -0.27 | -0.84 | -0.34 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.78 | 1.12 | 1.42 | 1.03 | 0.53 | |
| ROIC | 0.05 | 0.01 | 0 | 0.01 | -0.01 | |
| Return on tangible assets | 0.05 | 0.02 | -0.03 | 0.01 | 0 | |
| Graham Net | -0.13 | 0.66 | 0.7 | 0.75 | 0.74 | |
| Working capital | 366.79M | 373.13M | 374.23M | 419.33M | 409.37M | |
| Tangible asset value | 627.16M | 624.91M | 613.72M | 655.95M | 629.21M | |
| Net current asset value | 338.98M | 340.95M | 338.48M | 382.56M | 373.78M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 11.03M | 15.13M | 14.63M | 15.28M | 13.55M | |
| Average inventory | 42.27M | 40.93M | 45.19M | 54.67M | 43.79M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 72.79 | 164.98 | 105.8 | 108.6 | 8.91 | |
| Days of inventory on hand | 320.57 | 299.36 | 270.1 | 388.61 | 24.8 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 5.01 | 2.21 | 3.45 | 3.36 | 40.95 | |
| Inventory turnover | 1.14 | 1.22 | 1.35 | 0.94 | 14.72 | |
| ROE | 0.05 | 0.02 | -0.04 | 0.02 | 0 | |
| Capex per share | -0.04 | -0.04 | -0.02 | -0.06 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-06-30 | 2021-09-30 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.48 | 0.49 | 0.12 | 0.08 | 0.06 | |
| Net income per share | 0.01 | 0 | 0 | -0.01 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0.01 | 0.01 | -0.03 | -0.03 | -0.03 | |
| Cash per share | 1.04 | 1.07 | 1.06 | 1.03 | 1.05 | |
| Book value per share | 1.6 | 1.61 | 1.61 | 1.61 | 1.6 | |
| Tangible book value per share | 1.68 | 1.68 | 1.59 | 1.91 | 1.57 | |
| Share holders equity per share | 1.6 | 1.61 | 1.61 | 1.61 | 1.6 | |
| Interest debt per share | 0.03 | 0.03 | 0 | 0 | 0 | |
| Market cap | 3B | 2.87B | 6.7B | 4.73B | 3.94B | |
| Enterprise value | 2.9B | 2.78B | 6.61B | 4.61B | 3.86B | |
| P/E ratio | 335.27 | 422.39 | 2.01K | -358.3 | -1.16K | |
| Price to sales ratio | 15.67 | 14.63 | 140.81 | 154.79 | 159.54 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 1.03K | 586.89 | -570.36 | -354.87 | -391.4 | |
| P/B Ratio | 4.68 | 4.47 | 10.47 | 7.43 | 6.19 | |
| PTB ratio | 4.68 | 4.47 | 10.47 | 7.43 | 6.19 | |
| EV to sales | 15.15 | 14.14 | 139.01 | 151.02 | 156.34 | |
| Enterprise value over EBITDA | 1.98K | 952.71 | 4.02K | -2.65K | -20.71K | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 998.96 | 567.22 | -563.04 | -346.22 | -383.55 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0.3 | 0.31 | 0.17 | 0 | 0.17 | |
| Net debt to EBITDA | -67.76 | -33.03 | -52.32 | 66.17 | 423.76 | |
| Current ratio | 2.61 | 2.57 | 5.04 | 5.22 | 5.05 | |
| Interest coverage | 0 | -0.97 | 12.85 | -21.8 | -13.56 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0.2 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | -0.01 | 0.1 | 0.13 | -0.06 | 0.64 | |
| Research and developement to revenue | 0.01 | 0.02 | 0.08 | 0.21 | 0.19 | |
| Intangibles to total assets | 0.05 | 0.05 | 0.06 | 0.06 | 0.06 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.02 | -0.01 | -0.03 | -0.18 | -0.52 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.45 | 0.39 | 0.28 | 0.55 | 0.28 | |
| ROIC | 0 | 0 | 0 | -0.01 | -0.01 | |
| Return on tangible assets | 0 | 0 | 0 | 0 | 0 | |
| Graham Net | 0.43 | 0.43 | 0.76 | 1.09 | 0.77 | |
| Working capital | 438.32M | 447.75M | 415.26M | 412.68M | 404.03M | |
| Tangible asset value | 669.4M | 671.24M | 630.41M | 0 | 620.47M | |
| Net current asset value | 399.36M | 408.92M | 379.81M | 0 | 370.65M | |
| Invested capital | 0.02 | 0.02 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 88.53M | 95.5M | 13.74M | 14.63M | 13.33M | |
| Average inventory | 86.99M | 89.91M | 39.01M | 42.31M | 44.22M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 110.6 | 113.44 | 121.57 | 317.61 | 238.27 | |
| Days of inventory on hand | 89.67 | 88.46 | 338.11 | 918.21 | 913.74 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.81 | 0.79 | 0.74 | 0.28 | 0.38 | |
| Inventory turnover | 1 | 1.02 | 0.27 | 0.1 | 0.1 | |
| ROE | 0 | 0 | 0 | -0.01 | 0 | |
| Capex per share | -0.01 | -0.01 | 0 | -0.01 | -0.03 |
002750.SZ Frequently Asked Questions
What is Kunming Longjin Pharmaceutical Co., Ltd. stock symbol ?
Kunming Longjin Pharmaceutical Co., Ltd. is a CN stock and trading under the symbol 002750.SZ
What is Kunming Longjin Pharmaceutical Co., Ltd. stock quote today ?
Kunming Longjin Pharmaceutical Co., Ltd. stock price is $13.26 today.
Is Kunming Longjin Pharmaceutical Co., Ltd. stock public?
Yes, Kunming Longjin Pharmaceutical Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 33.57M
- Market Capitalization 5.31B
- Employee 517
- Headquarters Kunming,CN
- IPO Date 2015-03-24
-
Website
https://www.longjin.com.cn 
Kunmig Longjin Pharmaceutical Co., Ltd. develops, produces, and sells natural botanicals and chemical freeze-dried powder injections in China. The company offers Chinese, biochemical, chemical, cardio-cerebral vascular, and digestive system medicines; immune system and first aid medications; and vitamins, minerals, and enteral and parenteral nutrition products. It also engages in the industrial hemp plantation business. The company was founded in 1996 and is headquartered in Kunming, China.
